While direct evidence of dapagliflozin’s modulation of the PI3K-Akt, MAPK, and AGE-RAGE pathways specifically in CKD models is limited, several studies suggest its influence on these pathways in related contexts. The gene discussed is AKT1; the disease is chronic kidney disease.